Biallelic constitutional mutations in DNA mismatch repair genes cause a distinct syndrome, constitutional mismatch repair deficiency syndrome (CMMRD), characterized by cancers from multiple organs, most commonly brain tumors, during childhood. Surveillance protocols include total and brain MR imaging among other modalities to enable early detection of tumors. Brain surveillance scans revealed prominent brain developmental venous anomalies (DVAs) in some patients. DVAs are benign vascular anomalies, and their incidence in the general population is 2.6%-6.4%. Most developmental venous anomalies are asymptomatic and are found incidentally. Our purpose was to assess the prevalence of DVAs in CMMRD patients and describe their phenotype.
C onstitutional mismatch repair deficiency syndrome (CMMRD) is a cancer-predisposition syndrome characterized mainly by a high risk for developing cancer in childhood and young adulthood as well as nonmalignant features. The most common malignancies are brain tumors (predominantly malignant gliomas, though other tumors are reported), lymphoid malignancies (most commonly non-Hodgkins lymphomas and leukemia), and gastrointestinal cancers (Lynch syndrome-associated tumors, especially colorectal cancer). 1, 2 Nonmalignant manifestations of the syndrome include benign tumors such as adenomas and neurofibromas, features of neurofibromatosis type 1, predominantly café au lait macules, other hypo-and hyperpigmented skin alterations, pilomatricomas, and other features that were included in the suggested diagnostic criteria by the European Consortium. 1 Because CMMRD is a cancer-predisposition syndrome with a very high penetrance and most reported individuals are affected during childhood, surveillance protocols were developed aiming at early detection and interventions of these cancers. MR imaging
of the brain, every 6 months, starting at diagnosis or birth, is part of the surveillance protocol recommended for these children by the European Consortium Care for CMMR-D 3 and the International Biallelic Mismatch Repair Deficiency Consortium. 2, 4 It is important to arrive at a definite diagnosis of CMMRD in a pediatric or young adult patient with cancer as early as possible to allow the recommended surveillance for the patient and genetic counseling for family members. To facilitate CMMRD testing in patients with cancer, the European Consortium Care for CMMR-D suggested a score based on diagnostic criteria. 1 In the suggested score, several features of the syndrome are assigned points; a patient with a 3-point score or above is referred for genetic counseling. In Tel Aviv Sourasky medical center, we noted prominent developmental venous anomalies (DVAs) on routine brain MR imaging performed as a part of our surveillance protocol in patients with CMMRD. DVA is the most frequently encountered cerebral vascular malformation, with an incidence of 2.6%-6.4% in different studies. 5, 6 A DVA is characterized by a cluster of venous radicles that converge into a collecting vein, resulting in the typical caput medusa appearance of the DVA. 7 The collecting vein crosses a variable length of brain parenchyma to join either the superficial or deep venous system. Two or more DVAs coexisting in separate regions of the brain were observed in 7%-16% of described patients with DVAs. 8, 9 Most DVAs are asymptomatic and are found incidentally. However, DVAs have been documented as a rare cause of cerebrovascular bleeding and ischemic events. 7 There is a known association between DVAs and cavernomas. 6, 7 Our aim was to assess the prevalence of DVAs in children with CMMRD and to describe their phenotype to elucidate possible distinct features associated with CMMRD.
MATERIALS AND METHODS
We performed detailed clinical and imaging analysis of all children from 3 different families that are carriers of DNA mismatch repair genes, each family with a distinct type of mutation. The first family has a PMS2 mutation (c.2458dupA), with 5 affected homozygous members. The second family has a MSH6 mutation [c.2314cϾT (p.Arg772Trp)], with 2 affected homozygous members. The third family has 2 different pathogenic mutations in MSH6 (c.3984_3987dupGTCA//c.3959_3962delCAAG), with 3 affected members who are compound heterozygotes.
All children had surveillance brain MR imaging during the past 10 years. This retrospective study was approved by Tel Aviv Sourasky medical center institutional review board. A retrospective descriptive analysis of their brain MR imaging studies included the number of DVAs, location, draining vessels (peripheral or central), length and diameter of the collecting vein, associated parenchymal changes (as reflected by increased T2WI signal intensity), and the presence of associated cavernomas. Correlation with coexisting brain tumor presence and location was also performed. Descriptive statistics were performed with SPSS (IBM, Armonk, New York).
RESULTS
Brain MR imaging studies of 10 children with CMMRD were evaluated. The complete patient information is presented in the On-line Table. There were 6 boys and 4 girls. The age at the earliest study available per child ranged from 1.0 to 12.0 years (mean, 6.5 years). Seven children were treated for CNS tumors (4 glioblastoma multiforme, 1 medulloblastoma, 1 gliomatosis cerebri, and 1 cord primitive neuroectodermal tumor), 1 child was treated for acute myeloid leukemia (AML), and 2 children were treated for lymphoma. Colon polyposis was present in 6 children, and adenocarcinoma of the colon, in 1 child. DVAs were noted in all children, constituting 100% prevalence. Five children had 2 DVAs, 1 child had 3 DVAs (Fig 1) , 3 children had 5 DVAs, and 1 child had 7 DVAs. In total, 35 DVAs were observed; 83% were in the supratentorial brain and 64% drained to peripheral cortical veins. The diameters of the collecting veins ranged from a minimum of 0.8 mm to a maximum of 3.0 mm (average, 1.9 mm; median, 1.8 mm; mode, 2.2 mm). The length of the collecting vein ranged from a minimum of 5.0 mm to a maximum of 39.0 mm (average, 24.9 mm; median, 27.0 mm; mode, 30.0 mm). There were T2 signal changes in the brain parenchyma adjacent to the DVA in 26% of DVAs (Fig 2) .
In children with brain tumors, there was no correlation between the tumor locations and the location of the DVA. Cavernomas were present in 2 patients. One patient with a brain tumor had a single small cavernoma adjacent to the DVA before therapy; on follow-up studies, after tumor treatment with radiation therapy, he developed focal bleeding in the known cavernoma and bleeding in additional therapy-induced multiple cavernomas that were not apparent on the initial study. A second patient had 2 non-therapy-induced cavernomas present but distant from the DVA. For 9 children, follow-up studies were available; the time between first and last available studies ranged from 0.2 to 7.5 years, and there was no change in the number of DVAs on follow-up studies.
DISCUSSION
In this study, we observed 100% prevalence of multiple DVAs in children with CMMRD. This is strikingly different from the prevalence of DVAs in the healthy population, which was reported as 2.7% in a study based on postmortem evaluation, 5 and 6.4% in a more recent study based on modern MR imaging. 6 Gökçe et al 6 evaluated 1165 patients with brain MR imaging studies and found DVAs in 75 patients; of those, 10 had multiple DVAs, which is 0.9% of their total evaluated population and 13.3% of the group of patients who had DVAs. The phenotypic characteristics of the DVAs in their study included 73% supratentorial location, 50% drainage to peripheral veins, and a collecting vein diameter range of 1.0 -4.3 mm (median, 2.0 mm). These findings are not significantly different from ours with 83% supratentorial location, 64% drainage to peripheral veins, and a collecting vein diameter range of 0.8 -3.0 mm (median, 1.8 mm). We found associated T2 signal changes in the parenchyma adjacent to the DVA in 26% of the DVAs, which is within the range of those reported in different studies: 7.8%, 10 11.6%, 8 and 28%. 11 The phenotypic similarities of the DVAs in our study group compared with those reported in the general population exclude morphologic unique features of this vascular malformation in CMMRD patients.
An increased prevalence of DVAs was reported in association with extensive head and neck venolymphatic malformations. In a series of 40 patients with facial venous malformations, 20% had associated DVAs and 12.5% had multiple DVAs. 12 In a series of 33 patients with orbital and periorbital lymphatic or venolymphatic malformations, up to 60% of patients had associated DVAs. 13 We did not encounter associated head and neck vascular malformations in our study population, and we did not find an association between CMMRD and vascular malformations in the literature. It has been suggested that DVAs may be part of intracranial manifestations of neurocutaneous disorders because there are case reports describing an association between DVAs and blue rubber bleb nevus syndrome. 14, 15 Patients with CMMRD have not been reported to have any association with blue rubber bleb nevus syndrome, but there is a known phenotypic overlap with neurofibromatosis type 1, most commonly café-au-lait macules. 16 However, there are no known reports describing the prevalence of DVAs in patients with neurofibromatosis type 1. From our experience (unpublished data), the prevalence of DVAs in the neurofibromatosis type 1 population is not as high as that seen in this study. Baas et al 17 reported an association between corpus callosum agenesis, gray matter heterotopia, and CMMRD; these findings were not present in our study group.
Jones et al 18 reported an increased prevalence of DVAs in a population of patients with primary brain tumors compared with the healthy population; in their study, 10.2% of patients with brain tumors had a DVA present compared with 5.3% of the control group. Among patients with DVAs, only 4 had Ͼ1 DVA. They did not find any correlation between the tumor and DVA locations, which is consistent with our results of no correlation between tumor site and DVA location. In their study, they did not mention whether children with CMMRD were included among the patients with brain tumors. Among studies describing patients with CM-MRD, in a French cohort of 31 patients, 19 there was mention of only 2 patients with intracranial angiomas; assuming the term "angioma" represents a DVA, this finding is very different from the prevalence in our study. In the French cohort, the description of intracranial abnormalities is based on patients' physician reports and not on dedicated evaluation of brain MR imaging by a neuroradiologist. Because a DVA may be considered a normal variant, its mention may be omitted from radiology reports; this may explain the discrepancy. Most studies describing patients with CMMRD are dedicated to the clinical course and genetics; we did not find, to date, an additional description of associated intracranial vascular malformations.
In a child with a tumor, clinical suspicion of CMMRD arises when coexistence of several features is observed. These include a consanguineous family, café au-lait spots (possibly mimicking neurofibromatosis type 1), and a family history of malignancies in young relatives, especially brain tumors, lymphomas, or leukemias. Indeed, these and additional clinical manifestations were recently suggested to serve as criteria for a clinical diagnosis of CMMRD. 1 Our data suggest that the presence of multiple DVAs in an MR imaging of the brain with an associated brain tumor or other CMMRD-related malignancy can be another clue to the diagnosis. This marker can be especially helpful to determine the clinical diagnosis of CMMRD in individuals who are unaffected by cancer and in whom the genetic tests are inconclusive. Most interesting, in 2 patients, in whom there was clinical suspicion of CMMRD, the lack of DVAs was associated with negative molecular evidence of CMMRD (unpublished data).
The main limitation of this study is the small group of patients. MR imaging study of a boy who is homozygote for the PMS2 mutation and has 2 DVAs demonstrates increased T2 signal in the left frontal white matter on axial T2WI (A). This is associated with a subtle DVA (arrow) depicted in the axial T1WI postgadolinium injection (B).
Further assessment of larger patient cohorts from the international consortia will further delineate the exact prevalence of DVAs and the characteristics of DVAs in this patient population. However, the presence of multiple DVAs in all patients in this study has no parallel description in any other pathology, supporting the important role of DVAs for the clinical diagnosis of CMMRD.
CONCLUSIONS
Our cohort had 100% prevalence of multiple CNS DVAs in patients with CMMRD. If confirmed, this quantifiable feature can be added to the current scoring system and result in early implementation of genetic testing and surveillance protocols, which can be life-saving for these patients and families as well as allowing targeted tumor management. 20, 21 
